Quinupristin/dalfopristin: Difference between revisions
CSV import |
CSV import |
||
| Line 26: | Line 26: | ||
{{stub}} | {{stub}} | ||
== Quinupristin/dalfopristin == | |||
<gallery> | |||
File:Quinupristin.png|Quinupristin | |||
File:Dalfopristin chemical structure.png|Dalfopristin chemical structure | |||
</gallery> | |||
Latest revision as of 01:08, 20 February 2025
Quinupristin/dalfopristin is a combination of two antibiotics, quinupristin and dalfopristin, used to treat infections by bacteria. It is marketed by the pharmaceutical company Pfizer under the brand name Synercid.
Etymology[edit]
The name "quinupristin" is derived from the chemical structure of the drug, which contains a quinuclidine ring. The name "dalfopristin" is also derived from the chemical structure, which contains a dalfo ring.
Pharmacology[edit]
Quinupristin/dalfopristin is a streptogramin antibiotic, which means it inhibits the synthesis of bacterial proteins, leading to the death of the bacteria. It is used to treat serious or life-threatening infections caused by susceptible strains of Staphylococcus aureus, Streptococcus pneumoniae, and certain Enterococcus species.
Clinical use[edit]
Quinupristin/dalfopristin is used to treat vancomycin-resistant Enterococcus faecium (VREF) infections, as well as skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) and Streptococcus pyogenes. It is also used in the treatment of bacteremia.
Side effects[edit]
Common side effects of quinupristin/dalfopristin include pain and inflammation at the injection site, nausea, vomiting, rash, and diarrhea. Serious side effects can include allergic reactions, damage to the liver, and superinfections with resistant organisms.
